Education
About Us
Working with TipRanks
Follow Us
NextCure Inc (NXTC)
NASDAQ:NXTC
NXTC Stock Chart & Stats
$13.73
-$0.05(-5.92%)
At close: 4:00 PM EST
$13.73
-$0.05(-5.92%)
Day’s Range― - ―
52-Week Range$2.69 - $15.74
Previous CloseN/A
Volume33.57K
Average Volume (3M)37.58K
Market Cap
$35.57M
Enterprise Value$5.94M
Total Cash (Recent Filing)$41.82M
Total Debt (Recent Filing)$5.15M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Apr 30, 2026EPS Estimate
-1.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding3,560,410
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.28
Enterprise Value/Ebitda-0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.22
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ADC Pipeline Progress & PlatformAdvancing two ADC programs toward Phase 1 readouts showcases the company’s discovery-to-clinic capability and its proprietary immunomedicine platform. Durable clinical progress can materially de-risk programs, attract partners, and create long-term value if dose‑optimization and initial safety signals are positive.
Low Financial LeverageVery low reported debt reduces solvency and interest burden risk for a cash‑consuming biotech. This structural strength preserves financial flexibility to raise capital or secure collaborations without heavy fixed obligations, improving the company’s ability to sustain development programs over the medium term.
Near-term Cash RunwayA disclosed runway into the first half of 2027 provides a tangible time window to advance dose escalation, generate early clinical data, and pursue partnerships or milestone-based funding. This runway supports executing near-term development milestones central to value creation over the next 6–12 months.
Bears Say
Pre-revenue With Sizable LossesThe company remains a pre-revenue clinical biotech with recurring multi‑year losses, meaning no internal product cash generation. Persistent negative earnings force dependence on external capital, lengthen the path to self‑sustaining operations, and magnify execution risk if clinical outcomes or financing conditions deteriorate.
Consistent Negative Cash FlowSustained negative operating and free cash flow indicates ongoing cash burn to support trials. This structural cash outflow pattern requires recurrent financing, increases dilution risk, and constrains the company’s ability to internally fund multiple parallel development programs or respond to unexpected trial delays.
Shrinking Equity Base / Dilution RiskA pronounced decline in shareholders’ equity reflects accumulated deficits and past dilution, limiting balance sheet capacity to absorb losses. Combined with disclosed at‑the‑market offering risk, this structural weakness raises the likelihood of further equity issuance and long‑term dilution unless clinical progress leads to non‑dilutive partnerships.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $2.69 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $35.57M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Apr 30, 2026 which is in 38 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Mar 05, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$2.29 by $1.83.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Overvalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -1.83.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 3,560,410 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$0.46 in its last earnings report, beating expectations of -$2.29. Following the earnings report the stock price went down -2.9%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NextCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.18%
12-Months-Change
Fundamentals
Return on Equity
-152.90%
Trailing 12-Months
Asset Growth
-37.65%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Technical Analysis
Ownership Overview
―
Insiders
6.91% Mutual Funds
45.47% Other Institutional Investors
44.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---